Every material Form 8-K Lunai Bioworks Inc. has filed with the SEC since June 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lunai Bioworks received a Nasdaq determination that it no longer meets the $2,500,000 minimum stockholders' equity requirement, citing a stockholders' deficit of $(9,024,946). The company's board approved voluntary withdrawal of its common stock from Nasdaq and from registration under the Exchange Act, and it will not request a hearing. Trading on Nasdaq is expected to be suspended on October 30, 2026, and shareholders may have no over-the-counter quotation or trading market after that.
Stockholders' deficit of $(9,024,946) in the fiscal year ended June 30, 2026 10-K, versus the $2,500,000 minimum
Nasdaq trading expected to be suspended at the opening of business on October 30, 2026, unless a hearing is requested by October 28, 2026; the company does not intend to request one
Form 25 expected on or about November 2, 2026, with delisting effective on or about November 12, 2026
Chief Financial Officer Nathen Fuentes resigned effective October 22, 2026, with no successor appointed; the company does not intend to quote its stock over the counter
Lunai Bioworks asked Nasdaq on October 9, 2026 to immediately suspend trading in its stock, citing trading records from its pending Delaware litigation that it says raise serious questions about whether trading has occurred in a fair and orderly market. Nasdaq has not decided, and the request itself does not halt trading, so shareholders face uncertainty about whether trading will continue.
Request submitted to Nasdaq on October 9, 2026, asking for an immediate trading suspension while Nasdaq, FINRA and other authorities review trading records
Records cited include substantial short selling, locate deficiencies and concentrated failures to deliver, based on court-ordered discovery in Lunai Bioworks, Inc. v. Seven Points Capital LLC et al.
As of the filing, Nasdaq had not responded, and the company cannot predict if or when it will act; allegations have not been adjudicated
Lunai Bioworks furnished a letter from CEO David Weinstein to shareholders, distributed as a press release on June 17, 2026. The letter reports a lawsuit filed in May 2026 in the U.S. District Court for the District of Delaware against unidentified parties alleged to have engaged in naked short selling, and says the company is now in discovery. It also says the company has achieved compliance with NASDAQ listing requirements, but the filing contains no financial results, revenue figures, or guidance.
In May 2026, the company sued unidentified parties in the U.S. District Court for the District of Delaware over alleged naked short selling; the court found good cause for expedited discovery and the case is in discovery.
The letter says the company secured its first revenue-generating multi-year defense collaboration with BioSymetrics in April 2026; no contract value is disclosed.
The letter states the company has achieved compliance with NASDAQ listing requirements; no further details are given.
The filing reports no financial results, revenue amounts, or guidance.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lunai Bioworks Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →